BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33747255)

  • 21. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.
    Jiang S; Zhu L; Yang J; Hu L; Gu J; Xing X; Sun Y; Zhang Z
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):113-119. PubMed ID: 29050937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
    Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.
    He D; Huang C; Zhou Q; Liu D; Xiong L; Xiang H; Ma G; Zhang Z
    Oncotarget; 2017 Mar; 8(12):20165-20178. PubMed ID: 28423622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms.
    Fulcher LJ; Bozatzi P; Tachie-Menson T; Wu KZL; Cummins TD; Bufton JC; Pinkas DM; Dunbar K; Shrestha S; Wood NT; Weidlich S; Macartney TJ; Varghese J; Gourlay R; Campbell DG; Dingwell KS; Smith JC; Bullock AN; Sapkota GP
    Sci Signal; 2018 May; 11(531):. PubMed ID: 29789297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SKA3 Expression as a Prognostic Factor for Patients with Pancreatic Adenocarcinoma.
    Buchholz K; Durślewicz J; Klimaszewska-Wiśniewska A; Wiśniewska M; Słupski M; Grzanka D
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.
    Fang R; Zhang B; Lu X; Jin X; Liu T
    J Cell Biochem; 2020 Mar; 121(3):2458-2466. PubMed ID: 31692063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
    Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
    Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 29. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.
    Mo SJ; Liu X; Hao XY; Chen W; Zhang KS; Cai JP; Lai JM; Liang LJ; Yin XY
    Cancer Lett; 2016 Oct; 380(2):403-412. PubMed ID: 27378242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
    Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
    Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
    Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
    BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation, apoptosis, and invasion by sponging miR-625 and miR-892b.
    Hao L; Rong W; Bai L; Cui H; Zhang S; Li Y; Chen D; Meng X
    J Cell Biochem; 2019 Mar; 120(3):3780-3789. PubMed ID: 30382592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic analysis of the oncogenic role of FAM83D across cancers based on data mining.
    Geng Y; Liu J; Wang Z; Liu T; Peng X; Huang Y
    Cell Cycle; 2023 Apr; 22(8):1005-1019. PubMed ID: 36710419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
    Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
    J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.